Hyperlipidemia

A-aziz Sultan
A-aziz Sultanlacturer em Amoud University School of Pharmacy
Hyperlipidemia
CARDIOVASCULAR
DISORDERS
LECTURER: ABDIAZIZ SH: FARAH
HYPERLIPIDEMIA
❶ The risk of atherosclerosis is directly related to increasing levels of serum
cholesterol.
Hypercholesterolemia (elevation in serum cholesterol) and other
abnormalities in serum lipids play a major role in plaque formation leading to
coronary heart disease (CHD) as well as other forms of atherosclerosis, such
as carotid and peripheral artery disease (atherosclerosis of the peripheral
arteries). This predictive relationship has been demonstrated from large
epidemiologic,1 animal, and genetic studies. Coronary heart disease is the
leading cause of death in both men and women in the United States and
most industrialized nations.
It is also the chief cause of premature, permanent disability in the United
States work force.
Annually, approximately 700,000 Americans will suffer a new heart attack and
500,000 will have a recurrent event.
The average age of a first heart attack is 66 years for American men and 70
years for women. The direct and indirect cost of CHD to the United States
economy is almost $140 billion.
PATHOPHYSIOLOGY
Lipid and Lipoprotein Metabolism
Cholesterol is an essential substance manufactured by most cells in the
body. Cholesterol is used to maintain cell wall integrity and for the
biosynthesis of bile acids and steroid hormones. Other major lipids in our
body are triglycerides and phospholipids. Since cholesterol is a relatively
water-insoluble molecule, it is unable to circulate through the blood alone.
Cholesterol along with triglycerides and phospholipids are packaged in a
large carrier-protein called a lipoprotein (Fig. 9–1). Lipoproteins are water
soluble, which allows transportation of the major lipids in the blood. These
lipoproteins are spherical and vary in size (~1,000 to 6 nm) and density
(less than 0.94 to 1.21 g/mL)4 (Table 9–1).
PATHOPHYSIOLOGY
The amount of cholesterol and triglycerides vary by lipoprotein size. The
major lipoproteins in descending size and ascending density are
chylomicrons, very low-density lipoprotein (VLDL), intermediate-density
lipoprotein (IDL), low-density lipoprotein (LDL), and high-density
lipoprotein (HDL).
When clinical laboratories measure and report serum total cholesterol,
what they are measuring and reporting are total cholesterol molecules in
all the major lipoproteins. The estimated value of LDL cholesterol is found
using the following equation:
Conditions Associated with Angina
PATHOPHYSIOLOGY
The determinants of oxygen supply and demand are shown in Fig. 4–1.
Increases in heart rate, left ventricular wall tension, and cardiac
contractility increase the rate of myocardial oxygen consumption (MVO2).
Left ventricular wall tension is a function of blood pressure, left ventricular
end-diastolic volume, and ventricular wall thickness.
Physical exertion increases heart rate, blood pressure, and cardiac
contractility, and commonly precipitates ischemia and symptoms of
angina in patients with significant coronary atherosclerosis.
Medications that reduce heart rate, cardiac contractility, and/or ventricular
wall tension are commonly prescribed to prevent ischemic
symptoms in patients with chronic stable angina.
Hyperlipidemia
Coronary Atherosclerosis
The normal arterial wall consists of the intima, media, and adventitia, as
illustrated in Fig. 4–3A. The endothelium is located in the intima and
consists of a layer of endothelial cells that line the lumen of the artery and
form a selective barrier between the vessel wall and blood contents. The
internal elastic lamina separates the intima and media, where vascular
smooth muscle cells are found. The vascular adventitia comprises the
artery’s outer layer. Atherosclerotic lesions form in the sub endothelial
space between the endothelial cells and internal elastic lamina.
Dysfunction of the endothelium allows lipoproteins, predominantly low-
density lipoprotein (LDL) cholesterol, and inflammatory cells, namely
monocytes and T lymphocytes, to migrate from the plasma to the sub-
endothelial space.
Monocyte-derived macrophages ingest lipoproteins to form foam cells.
Macrophages also secrete growth factors that promote smooth muscle
cell migration from the media to the intima.
Hyperlipidemia
Hyperlipidemia
Hyperlipidemia
A fatty streak consists of lipid-laden macrophages and smooth muscle cells
and is the earliest type of atherosclerotic lesion.
Lipid-laden macrophages, smooth muscle cells, and necrotic debris from the
death of foam cells accumulate in the sub endothelial space, leading to
enlargement of the fatty streak. A collagen matrix forms a fibrous cap that
covers the lipid core of the lesion to establish a fibrous plaque called an
atherosclerotic plaque. Initially, the diameter of the coronary artery lumen is
maintained as the plaque grows outward (external to the lumen) in a process
referred to as arterial remodeling.9 However, with significant plaque
progression, the atherosclerotic plaque begins to protrude into the artery
lumen and impede blood flow.
When the plaque occludes 70% or more of the artery, the patient may begin to
experience angina during activities that increase myocardial oxygen demand
(i.e., chronic stable angina).
Other causes of pathophysiology
Stable versus Unstable Atherosclerotic Plaques
Atherosclerotic Plaque Rupture
Coronary Artery Vasospasm
Hyperlipidemia
Hyperlipidemia
Hyperlipidemia
Distinguishing Characteristics of Chronic Stable
Angina and Unstable Angina
Chronic stable angina should be distinguished from unstable angina
since the latter is associated with a greater risk for MI and death and
requires more aggressive treatment. Because the pathophysiology of
chronic stable angina is due primarily to increases in oxygen demand,
not acute changes in oxygen supply, symptoms are typically
reproducible and reversible.
Specifically, a patient will generally experience a similar pattern of
discomfort (i.e., same quality, location, and accompanying symptoms)
with a similar level of exertion with each angina attack.
Chronic stable angina is usually relieved within minutes by rest
or sublingual nitroglycerin.
In contrast, unstable angina is due to an acute decrease in coronary
blood flow leading to insufficient oxygen supply. Consequently, unstable
angina is marked by prolonged symptoms (greater than or equal to 20
minutes) or an escalation in the frequency or severity of angina over a
short period of time. Unstable angina frequently occurs at rest without
any precipitating factors, whereas chronic stable angina usually occurs
with exertion. Unstable angina may be less responsive to
rest or medication.
The presentation of unstable angina is described in greater detail in
Table 4–4.
Hyperlipidemia
TREATMENT
Desired Outcomes
Once the diagnosis of IHD is established in a patient, the clinician should
provide counseling on lifestyle modifications,
institute appropriate pharmacologic therapy, and evaluate the
need for surgical revascularization. ❹ The major goals for the
treatment of IHD are to:
• Prevent acute coronary syndromes and death;
• Alleviate acute symptoms of myocardial ischemia;
• Prevent recurrent symptoms of myocardial ischemia; and
• Avoid or minimize adverse treatment effects.
Hyperlipidemia
Hyperlipidemia
Hyperlipidemia
Percutaneous Coronary Intervention
Coronary Artery Bypass Graft Surgery
Pharmacologic Therapy
Hyperlipidemia
Hyperlipidemia
Hyperlipidemia
Hyperlipidemia
REFERNCE
pharmacotherapy_principles 2007-mcgraw-hill
DHAMAAD
1 de 32

Recomendados

Hyperlipidemia and its treatment por
Hyperlipidemia and its treatment Hyperlipidemia and its treatment
Hyperlipidemia and its treatment Komal Rajgire
21.5K visualizações41 slides
Hyperlipidemia.pptx por
Hyperlipidemia.pptxHyperlipidemia.pptx
Hyperlipidemia.pptxSHIVANEE VYAS
2.3K visualizações10 slides
HYPERLIPIDEMIA por
HYPERLIPIDEMIAHYPERLIPIDEMIA
HYPERLIPIDEMIAANAND SAGAR TIWARI
1.5K visualizações84 slides
Hyperlipidemia por
HyperlipidemiaHyperlipidemia
HyperlipidemiaJuliya Susan Reji
1.5K visualizações24 slides
Hyperlipidemia por
Hyperlipidemia Hyperlipidemia
Hyperlipidemia Sagar Bagul
967 visualizações18 slides
Hyperlipidemia por
HyperlipidemiaHyperlipidemia
HyperlipidemiaFaz Halim
2K visualizações13 slides

Mais conteúdo relacionado

Mais procurados

Hyperlipidemia por
Hyperlipidemia Hyperlipidemia
Hyperlipidemia Diana Rangaves, PharmD, CEO
22.2K visualizações27 slides
Hyperlipidemia por
HyperlipidemiaHyperlipidemia
HyperlipidemiaJaineel Dharod
14.6K visualizações46 slides
Hyperlipidemia por
HyperlipidemiaHyperlipidemia
HyperlipidemiaBasil Wilson
38.6K visualizações50 slides
Pathology of Hypertension por
Pathology of HypertensionPathology of Hypertension
Pathology of HypertensionShashidhar Venkatesh Murthy
69.9K visualizações30 slides
Hyperlipidemia pharmacotherapy por
Hyperlipidemia pharmacotherapyHyperlipidemia pharmacotherapy
Hyperlipidemia pharmacotherapyUrvi Kolhatkar
6.9K visualizações25 slides
Hyperlipidemia por
HyperlipidemiaHyperlipidemia
Hyperlipidemiayounis zainal
8.8K visualizações43 slides

Mais procurados(20)

Hyperlipidemia por Jaineel Dharod
HyperlipidemiaHyperlipidemia
Hyperlipidemia
Jaineel Dharod14.6K visualizações
Hyperlipidemia por Basil Wilson
HyperlipidemiaHyperlipidemia
Hyperlipidemia
Basil Wilson38.6K visualizações
Hyperlipidemia pharmacotherapy por Urvi Kolhatkar
Hyperlipidemia pharmacotherapyHyperlipidemia pharmacotherapy
Hyperlipidemia pharmacotherapy
Urvi Kolhatkar6.9K visualizações
Hyperlipidemia por younis zainal
HyperlipidemiaHyperlipidemia
Hyperlipidemia
younis zainal8.8K visualizações
Hyperlipidaemia por Darshan Vaghela
HyperlipidaemiaHyperlipidaemia
Hyperlipidaemia
Darshan Vaghela806 visualizações
Pathophysiology of congestive heart failure por thunderrajesh
Pathophysiology of congestive heart failurePathophysiology of congestive heart failure
Pathophysiology of congestive heart failure
thunderrajesh220.3K visualizações
SGLT 2 inhibitors por Naveen Kumar
SGLT 2 inhibitorsSGLT 2 inhibitors
SGLT 2 inhibitors
Naveen Kumar16.8K visualizações
Dyslipidemia management an evidence based approach por Dr Vivek Baliga
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approach
Dr Vivek Baliga2.8K visualizações
Management of Hyperlipidemia por Health Forager
Management of HyperlipidemiaManagement of Hyperlipidemia
Management of Hyperlipidemia
Health Forager11.6K visualizações
Statins por Lyndon Woytuck
StatinsStatins
Statins
Lyndon Woytuck13.4K visualizações
Hyperlipidemia and drug therapy for hyperlipidemia por akbar siddiq
Hyperlipidemia and drug therapy for hyperlipidemiaHyperlipidemia and drug therapy for hyperlipidemia
Hyperlipidemia and drug therapy for hyperlipidemia
akbar siddiq68.8K visualizações
Hyperlipidemia por Anvy Anvia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
Anvy Anvia741 visualizações
lipid-lowering drugs por Elham Khaled
lipid-lowering drugslipid-lowering drugs
lipid-lowering drugs
Elham Khaled22.8K visualizações
ACE Inhibitors por SMS MEDICAL COLLEGE
ACE InhibitorsACE Inhibitors
ACE Inhibitors
SMS MEDICAL COLLEGE26.9K visualizações

Similar a Hyperlipidemia

IHD ema_2020.pdf por
IHD ema_2020.pdfIHD ema_2020.pdf
IHD ema_2020.pdfImtiyaz60
17 visualizações55 slides
Cad por
CadCad
Cadriders23
1.1K visualizações15 slides
4 myocardial infraction por
4 myocardial infraction4 myocardial infraction
4 myocardial infractionChanukya Vanam . Dr
76 visualizações110 slides
3 angina pectoris por
3 angina pectoris3 angina pectoris
3 angina pectorisChanukya Vanam . Dr
84 visualizações94 slides
Artherosclerosis por
ArtherosclerosisArtherosclerosis
ArtherosclerosisDr. Bijay kumar Sah
510 visualizações31 slides
Lecture 7 diseases of the vascular system - Pathology por
Lecture 7 diseases of the vascular system - Pathology Lecture 7 diseases of the vascular system - Pathology
Lecture 7 diseases of the vascular system - Pathology Areej Abu Hanieh
1.6K visualizações27 slides

Similar a Hyperlipidemia(20)

IHD ema_2020.pdf por Imtiyaz60
IHD ema_2020.pdfIHD ema_2020.pdf
IHD ema_2020.pdf
Imtiyaz6017 visualizações
Cad por riders23
CadCad
Cad
riders231.1K visualizações
4 myocardial infraction por Chanukya Vanam . Dr
4 myocardial infraction4 myocardial infraction
4 myocardial infraction
Chanukya Vanam . Dr76 visualizações
Lecture 7 diseases of the vascular system - Pathology por Areej Abu Hanieh
Lecture 7 diseases of the vascular system - Pathology Lecture 7 diseases of the vascular system - Pathology
Lecture 7 diseases of the vascular system - Pathology
Areej Abu Hanieh1.6K visualizações
Cardiogenic shock por Abhay Rajpoot
Cardiogenic shockCardiogenic shock
Cardiogenic shock
Abhay Rajpoot69.2K visualizações
4. nursing manahement patient with myocardial infarction por AkashBhagwat3
4. nursing manahement patient with myocardial infarction4. nursing manahement patient with myocardial infarction
4. nursing manahement patient with myocardial infarction
AkashBhagwat3515 visualizações
Essay On Endothelium In Health And Disease por Susan Kennedy
Essay On Endothelium In Health And DiseaseEssay On Endothelium In Health And Disease
Essay On Endothelium In Health And Disease
Susan Kennedy2 visualizações
Congestive Heart Failure Research Paper por Julie Gonzalez
Congestive Heart Failure Research PaperCongestive Heart Failure Research Paper
Congestive Heart Failure Research Paper
Julie Gonzalez2 visualizações
ARTERIOSCLEROSIS.pptx por SAMOEINESH
ARTERIOSCLEROSIS.pptxARTERIOSCLEROSIS.pptx
ARTERIOSCLEROSIS.pptx
SAMOEINESH63 visualizações
coronary artery disease por Sowmya Shetty
coronary artery diseasecoronary artery disease
coronary artery disease
Sowmya Shetty131 visualizações
The Complications Associated With Diabetes Mellitus ( Dm ) por Lori Bowie
The Complications Associated With Diabetes Mellitus ( Dm )The Complications Associated With Diabetes Mellitus ( Dm )
The Complications Associated With Diabetes Mellitus ( Dm )
Lori Bowie2 visualizações
A Brief Note On Coronary Artery Disease Prevention por Victoria Soto
A Brief Note On Coronary Artery Disease PreventionA Brief Note On Coronary Artery Disease Prevention
A Brief Note On Coronary Artery Disease Prevention
Victoria Soto2 visualizações
Atherosclerosis por JYOTI PACHISIA
AtherosclerosisAtherosclerosis
Atherosclerosis
JYOTI PACHISIA4.9K visualizações
Atherosclerosis por JYOTI PACHISIA
AtherosclerosisAtherosclerosis
Atherosclerosis
JYOTI PACHISIA3.7K visualizações
atherosclerosis.pptx por ajaybhat49
atherosclerosis.pptxatherosclerosis.pptx
atherosclerosis.pptx
ajaybhat4980 visualizações
SIHD& ACS.pptx por AbrhamMulatu
SIHD& ACS.pptxSIHD& ACS.pptx
SIHD& ACS.pptx
AbrhamMulatu12 visualizações
Atherosclerosis por Eneutron
AtherosclerosisAtherosclerosis
Atherosclerosis
Eneutron1.2K visualizações

Último

Children with Disabilities and Environmental Factors por
Children with Disabilities and Environmental FactorsChildren with Disabilities and Environmental Factors
Children with Disabilities and Environmental FactorsOlaf Kraus de Camargo
30 visualizações24 slides
Biomedicine & Pharmacotherapy por
Biomedicine & PharmacotherapyBiomedicine & Pharmacotherapy
Biomedicine & PharmacotherapyTrustlife
207 visualizações12 slides
Explore new Frontiers in Medicine with AI.pdf por
Explore new Frontiers in Medicine with AI.pdfExplore new Frontiers in Medicine with AI.pdf
Explore new Frontiers in Medicine with AI.pdfAnne Marie
16 visualizações31 slides
Correct handling of laboratory Rats ppt.pptx por
Correct handling of laboratory Rats ppt.pptxCorrect handling of laboratory Rats ppt.pptx
Correct handling of laboratory Rats ppt.pptxTusharChaudhary99
16 visualizações12 slides
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx por
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptxCMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptxJubinNath2
10 visualizações12 slides
BODY COMPOSITION.pptx por
BODY COMPOSITION.pptxBODY COMPOSITION.pptx
BODY COMPOSITION.pptxAneriPatwari
50 visualizações46 slides

Último(20)

Children with Disabilities and Environmental Factors por Olaf Kraus de Camargo
Children with Disabilities and Environmental FactorsChildren with Disabilities and Environmental Factors
Children with Disabilities and Environmental Factors
Olaf Kraus de Camargo30 visualizações
Biomedicine & Pharmacotherapy por Trustlife
Biomedicine & PharmacotherapyBiomedicine & Pharmacotherapy
Biomedicine & Pharmacotherapy
Trustlife207 visualizações
Explore new Frontiers in Medicine with AI.pdf por Anne Marie
Explore new Frontiers in Medicine with AI.pdfExplore new Frontiers in Medicine with AI.pdf
Explore new Frontiers in Medicine with AI.pdf
Anne Marie16 visualizações
Correct handling of laboratory Rats ppt.pptx por TusharChaudhary99
Correct handling of laboratory Rats ppt.pptxCorrect handling of laboratory Rats ppt.pptx
Correct handling of laboratory Rats ppt.pptx
TusharChaudhary9916 visualizações
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx por JubinNath2
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptxCMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
JubinNath210 visualizações
BODY COMPOSITION.pptx por AneriPatwari
BODY COMPOSITION.pptxBODY COMPOSITION.pptx
BODY COMPOSITION.pptx
AneriPatwari50 visualizações
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl... por DipeshGamare
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...
DipeshGamare18 visualizações
Buccoadhesive drug delivery System.pptx por ABG
Buccoadhesive drug delivery System.pptxBuccoadhesive drug delivery System.pptx
Buccoadhesive drug delivery System.pptx
ABG162 visualizações
Epilepsy and Anti epileptic drugs .pdf por A. Gowtham Sashtha
Epilepsy and Anti epileptic drugs .pdfEpilepsy and Anti epileptic drugs .pdf
Epilepsy and Anti epileptic drugs .pdf
A. Gowtham Sashtha16 visualizações
Complications & Solutions in Laparoscopic Hernia Surgery.pptx por Varunraju9
Complications & Solutions in Laparoscopic Hernia Surgery.pptxComplications & Solutions in Laparoscopic Hernia Surgery.pptx
Complications & Solutions in Laparoscopic Hernia Surgery.pptx
Varunraju9134 visualizações
Examining Pleural Fluid.pptx por Fareeha Riaz
Examining Pleural Fluid.pptxExamining Pleural Fluid.pptx
Examining Pleural Fluid.pptx
Fareeha Riaz 21 visualizações
vitamin E.pptx por ajithkilpart
vitamin E.pptxvitamin E.pptx
vitamin E.pptx
ajithkilpart13 visualizações
eTEP -RS Dr.TVR.pptx por Varunraju9
eTEP -RS Dr.TVR.pptxeTEP -RS Dr.TVR.pptx
eTEP -RS Dr.TVR.pptx
Varunraju9145 visualizações
Cholera Romy W. (3).pptx por rweth613
Cholera Romy W. (3).pptxCholera Romy W. (3).pptx
Cholera Romy W. (3).pptx
rweth61369 visualizações
PATIENTCOUNSELLING in.pptx por skShashi1
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptx
skShashi143 visualizações
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad por Swetha rani Savala
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Swetha rani Savala21 visualizações
Gastro-retentive drug delivery systems.pptx por ABG
Gastro-retentive drug delivery systems.pptxGastro-retentive drug delivery systems.pptx
Gastro-retentive drug delivery systems.pptx
ABG227 visualizações
Structural Racism and Public Health: How to Talk to Policymakers and Communit... por katiequigley33
Structural Racism and Public Health: How to Talk to Policymakers and Communit...Structural Racism and Public Health: How to Talk to Policymakers and Communit...
Structural Racism and Public Health: How to Talk to Policymakers and Communit...
katiequigley331.4K visualizações

Hyperlipidemia

  • 3. HYPERLIPIDEMIA ❶ The risk of atherosclerosis is directly related to increasing levels of serum cholesterol. Hypercholesterolemia (elevation in serum cholesterol) and other abnormalities in serum lipids play a major role in plaque formation leading to coronary heart disease (CHD) as well as other forms of atherosclerosis, such as carotid and peripheral artery disease (atherosclerosis of the peripheral arteries). This predictive relationship has been demonstrated from large epidemiologic,1 animal, and genetic studies. Coronary heart disease is the leading cause of death in both men and women in the United States and most industrialized nations. It is also the chief cause of premature, permanent disability in the United States work force. Annually, approximately 700,000 Americans will suffer a new heart attack and 500,000 will have a recurrent event. The average age of a first heart attack is 66 years for American men and 70 years for women. The direct and indirect cost of CHD to the United States economy is almost $140 billion.
  • 4. PATHOPHYSIOLOGY Lipid and Lipoprotein Metabolism Cholesterol is an essential substance manufactured by most cells in the body. Cholesterol is used to maintain cell wall integrity and for the biosynthesis of bile acids and steroid hormones. Other major lipids in our body are triglycerides and phospholipids. Since cholesterol is a relatively water-insoluble molecule, it is unable to circulate through the blood alone. Cholesterol along with triglycerides and phospholipids are packaged in a large carrier-protein called a lipoprotein (Fig. 9–1). Lipoproteins are water soluble, which allows transportation of the major lipids in the blood. These lipoproteins are spherical and vary in size (~1,000 to 6 nm) and density (less than 0.94 to 1.21 g/mL)4 (Table 9–1).
  • 5. PATHOPHYSIOLOGY The amount of cholesterol and triglycerides vary by lipoprotein size. The major lipoproteins in descending size and ascending density are chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). When clinical laboratories measure and report serum total cholesterol, what they are measuring and reporting are total cholesterol molecules in all the major lipoproteins. The estimated value of LDL cholesterol is found using the following equation:
  • 7. PATHOPHYSIOLOGY The determinants of oxygen supply and demand are shown in Fig. 4–1. Increases in heart rate, left ventricular wall tension, and cardiac contractility increase the rate of myocardial oxygen consumption (MVO2). Left ventricular wall tension is a function of blood pressure, left ventricular end-diastolic volume, and ventricular wall thickness. Physical exertion increases heart rate, blood pressure, and cardiac contractility, and commonly precipitates ischemia and symptoms of angina in patients with significant coronary atherosclerosis. Medications that reduce heart rate, cardiac contractility, and/or ventricular wall tension are commonly prescribed to prevent ischemic symptoms in patients with chronic stable angina.
  • 9. Coronary Atherosclerosis The normal arterial wall consists of the intima, media, and adventitia, as illustrated in Fig. 4–3A. The endothelium is located in the intima and consists of a layer of endothelial cells that line the lumen of the artery and form a selective barrier between the vessel wall and blood contents. The internal elastic lamina separates the intima and media, where vascular smooth muscle cells are found. The vascular adventitia comprises the artery’s outer layer. Atherosclerotic lesions form in the sub endothelial space between the endothelial cells and internal elastic lamina. Dysfunction of the endothelium allows lipoproteins, predominantly low- density lipoprotein (LDL) cholesterol, and inflammatory cells, namely monocytes and T lymphocytes, to migrate from the plasma to the sub- endothelial space. Monocyte-derived macrophages ingest lipoproteins to form foam cells. Macrophages also secrete growth factors that promote smooth muscle cell migration from the media to the intima.
  • 13. A fatty streak consists of lipid-laden macrophages and smooth muscle cells and is the earliest type of atherosclerotic lesion. Lipid-laden macrophages, smooth muscle cells, and necrotic debris from the death of foam cells accumulate in the sub endothelial space, leading to enlargement of the fatty streak. A collagen matrix forms a fibrous cap that covers the lipid core of the lesion to establish a fibrous plaque called an atherosclerotic plaque. Initially, the diameter of the coronary artery lumen is maintained as the plaque grows outward (external to the lumen) in a process referred to as arterial remodeling.9 However, with significant plaque progression, the atherosclerotic plaque begins to protrude into the artery lumen and impede blood flow. When the plaque occludes 70% or more of the artery, the patient may begin to experience angina during activities that increase myocardial oxygen demand (i.e., chronic stable angina).
  • 14. Other causes of pathophysiology Stable versus Unstable Atherosclerotic Plaques Atherosclerotic Plaque Rupture Coronary Artery Vasospasm
  • 18. Distinguishing Characteristics of Chronic Stable Angina and Unstable Angina Chronic stable angina should be distinguished from unstable angina since the latter is associated with a greater risk for MI and death and requires more aggressive treatment. Because the pathophysiology of chronic stable angina is due primarily to increases in oxygen demand, not acute changes in oxygen supply, symptoms are typically reproducible and reversible. Specifically, a patient will generally experience a similar pattern of discomfort (i.e., same quality, location, and accompanying symptoms) with a similar level of exertion with each angina attack. Chronic stable angina is usually relieved within minutes by rest or sublingual nitroglycerin.
  • 19. In contrast, unstable angina is due to an acute decrease in coronary blood flow leading to insufficient oxygen supply. Consequently, unstable angina is marked by prolonged symptoms (greater than or equal to 20 minutes) or an escalation in the frequency or severity of angina over a short period of time. Unstable angina frequently occurs at rest without any precipitating factors, whereas chronic stable angina usually occurs with exertion. Unstable angina may be less responsive to rest or medication. The presentation of unstable angina is described in greater detail in Table 4–4.
  • 21. TREATMENT Desired Outcomes Once the diagnosis of IHD is established in a patient, the clinician should provide counseling on lifestyle modifications, institute appropriate pharmacologic therapy, and evaluate the need for surgical revascularization. ❹ The major goals for the treatment of IHD are to: • Prevent acute coronary syndromes and death; • Alleviate acute symptoms of myocardial ischemia; • Prevent recurrent symptoms of myocardial ischemia; and • Avoid or minimize adverse treatment effects.

Notas do Editor

  1. impede = interfere with the movement, progress, or development of something
  2. ACS = acute coronary syndrome
  3. ACS = acute coronary syndrome
  4. Acute coronary syndrome is a term given by doctors for various heart conditions, including a myocardial infarction (heart attack) and unstable angina. These conditions are due to there being a reduced amount of blood flowing to a part of the heart.
  5. Laden = heavily loaded
  6. BMS, bare metal stent; CABG, coronary artery bypass graft; DES, drug-eluting stent; IR, immediate-release; LA, long-acting; LDL, low-density lipoprotein; LV, left ventricular; NTG, nitroglycerin; PCI, percutaneous coronary intervention; SL, sublingual.